EmbectaEMBC -5.20%53 5-Year Yield-on-Cost % is 14.41 as of Jul. 08, 2026, which is 247% above its 10-year median of 4.15. GuruFocus rates EMBC with a GF Score™ of 53/100 and a GF Value™ of $12.68 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Embecta ranks better than 93.27% on this metric.
Embecta's yield on cost for the quarter that ended in Mar. 2026 was 14.41.
The historical rank and industry rank for Embecta's 5-Year Yield-on-Cost % or its related term are showing as below:
EMBC'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.44 Med: 4.15 Max: 19.35
Current: 14.41
During the past 7 years, Embecta's highest Yield on Cost was 19.35. The lowest was 0.44. And the median was 4.15.
EMBC's 5-Year Yield-on-Cost % is ranked better than 93.27% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.31
vs EMBC: 14.41
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Embecta 5-Year Yield-on-Cost % Related Terms
EMBC vs KRMD, SMTI, PDEX: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Embecta's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embecta 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embecta's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Embecta's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Embecta is calculated as
Embecta (EMBC) has a 5-Year Yield-on-Cost % of 14.41 as of Jul. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Embecta and its competitors. This is 247% above median its historical median of 4.15. Over the past decade, Embecta's 5-Year Yield-on-Cost % has ranged from 0.44 to 19.35. According to the industry distribution chart, Embecta ranks #22 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 6.7%.
Is Embecta's 5-Year Yield-on-Cost % too high?
Embecta's current 5-Year Yield-on-Cost % of 14.41 is 247% above median its 10-year median of 4.15. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 19.35. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.31. Embecta's value of 14.41 is 523.8% above this industry median. Based on the distribution chart, Embecta ranks #22 out of 327 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embecta has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Embecta's 5-Year Yield-on-Cost % compare to KRMD and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Embecta ranks #22 out of 327 companies for 5-Year Yield-on-Cost %. This places Embecta in the top 7% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.31. Embecta's value of 14.41 is 523.8% above this benchmark. Historically, Embecta's own 5-Year Yield-on-Cost % has ranged from 0.44 to 19.35 over the past decade. While the company's 10-year median is 4.15 vs. the industry median of 2.31, Embecta has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.31, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embecta's current 5-Year Yield-on-Cost % of 14.41 is 523.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Embecta and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embecta's current 5-Year Yield-on-Cost % is 14.41, which is 247% above median its own 10-year median of 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Based on GuruFocus' analysis, Embecta (EMBC) is currently considered Possible Value Trap. The stock's GF Value™ is $12.68, compared to a current price of $3.19 — trading 74.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 14.41, which is 247% above median its 10-year median of 4.15 and 523.8% above the Medical Devices & Instruments industry median of 2.31. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Embecta (EMBC), the current 5-Year Yield-on-Cost % is 14.41 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embecta (EMBC) Overvalued in 2026?
Based on GuruFocus' analysis, Embecta stock appears to be undervalued.
The current stock price of $3.19 is trading 74.8% below its estimated GF Value™ of $12.68.
GuruFocus considers Embecta to be Possible Value Trap.
Key valuation signals for EMBC:
5-Year Yield-on-Cost %: 14.41 (247% above median its 10-year median of 4.15)
GF Value™: $12.68 vs. price of $3.19 (74.8% below fair value)
Industry Position: 523.8% above the Medical Devices & Instruments median (#22 of 327)
No single metric tells the full story. See the EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score
Get the complete analysis for EMBC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMBC has been successfully added to your 